道培医疗数据
CAR-T治疗
464
非血缘案例
915
亲缘半相同案例
3057
移植案例
4954

陆佩华 /陆道培医院医疗执行院长、美国血液病及肿瘤内科专家

简介:中国非公医疗协会第一届常务理事、中国非公立医疗机构协会血液病专业委员会主任委员。

擅长:细胞免疫治疗、淋巴瘤、骨髓瘤及白血病等的研究及治疗。


星期  
坐诊时间:【周一至周五(需提前电话预约)】
  • 医生履历
  • 科研荣誉
  • 学术论文
  • 专业经验:

    毕业于北京大学医学院,在美国内布拉斯加医学中心完成住院医,毕业于美国斯坦福大学血液及肿瘤专科。

    美国肿瘤以及血液病专科协会认证的血液及肿瘤专家,具有美国血液病专科医师,肿瘤专科医师执照以及中国行医执照。

    中国非公医疗协会第一届常务理事、

    中国非公立医疗机构协会血液病专业委员会主任委员、

    中国非公立医疗机构协会生物技术与细胞应用专业委员会常务委员、

    中国造血干细胞捐献者资料库专家委员会委员、

    中国临床肿瘤学会(CSCO)抗白血病联盟专家委员会常务委员、

    中国抗癌协会第一届血液病转化医学专业委员会常务委员。

    曾在国际知名学术杂志发表多篇论文,先后获得了多个美国国立卫生研究院(NIH)的奖项,包括个人的博士后研究奖及医生科学家奖(KO11)

    曾获得美国国家医学会的邀请在旧金山年会上作为外国医学院毕业生介绍个人在美的成功奋斗历程。

    5b0781b7ee960.jpg

    Lu, P. H., Negrin, R.S. A novel population of expanded human CD3+, CD56+ cells derived from T cells with potent in vivo antitumor activity in SCID mice.

    J. Immunol. 1994 153;1687.

    Lu, P.H., Negrin, R.S. Cellular immunotherapy following autologous hematopoietic progenitor transplantation.

    Biol Blood Marrow Transplant, 1997, 3(3);113-21.

    Pan J, Yang JF, Deng BP, Zhao XJ, Zhang X, Lin YH, Wu YN, Deng ZL, Zhang YL, Liu SH, Wu T, Lu PH, Lu DP, Chang AH, Tong CR.High efficacy and safety of low-dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukemia patients.

    Leukemia, 2017 Dec;31(12):2587-2593. doi: 10.1038/leu.2017.145. Epub 2017 May 15.

    Yang Zhang, Fang Wang, Xue Chen, Yu Zhang, Mingyu Wang, Hong Liu, Panxiang Cao, Xiaoli Ma, Tong Wang, Jianping Zhang, Xian Zhang, Peihua Lu#, and Hongxing Liu#.CSF3R mutations are frequently associated with abnormalities of RUNX1, CBFB,CEBPA, and NPM1 genes in acute myeloid leukemia.

    Cancer, 2018 Aug;124(16):3329-3338. doi: 10.1002/cncr.31586. Epub 2018 Jun 22.

    Saleem MS, Aljurf M, Srivastava A, Shamsi T, Lu PH, Hamidieh AA, El Haddad A, Hashmi SK. Challenges in managing graft-versus-host disease in developing countries: a perspective.

    Bone Marrow Transplant, 2018 Sep 20. doi: 10.1038/s41409-018-0333-z. [Epub ahead of print]

    Abstract:

    Lu, P.H. Negrin, R.S. Interleukin-12 promotes the expansion of CD3+CD56+ killer cells derived from CD3+CD56- T cells with enhanced cytotoxicity.

    Blood, 1994, Vol 84, No 10, Suppl: pp289a

    Lu, P.H. Negrin, R.S. A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in SCID mice.

    Blood, 1993, Vol 82, No 10, Suppl:pp188a (oral presentation at ASH in Dec.1993)

    Lu, P.H. Wang, Z and Negrin, R.S. Functional properties of clonal populations of CD3+CD56+ cells.  

    Blood, 1996, Vol 88, No 10, Suppl:pp42b.

    Lu, P.H. Wang, Z, Mehta, B and Negrin, R.S. Role of IL-12 and IL-15 in the ex vivo expansion, cytotoxicity and cytokine production of human CD3+CD56+ cells derived from T cells.

    Blood, 1996, Vol 88, No 10, Suppl:pp316a.

    Wang, Z, Lu, P.H. Weiner, G, Tso, Jand Negrn, R.S. Anti-CD3 X anti-1D10 bispecific antibody retargets and enhances the cytotoxicity of cytokine induced killer cells.

    Blood, 1996, Vol, No 1,Suppl:pp316a.

    Biping Deng, Alex Hongsheng Chang, Junfang Yang, Jing Pan, Xian Zhang, Yuehui Lin, Yanan Wu, Zhenling Deng, Peihua Lu, Tong Wu, Zhaoli Liu, Chunrong Tong. Safety and efficacy of low dose CD19-CART therapy in 47 cases with relapsed refractory B-cell acute lymphoblastic leukemia(B-ALL).

    ASH, December 3-6, 2016, oral presentation.

    Xian Zhang1*, Xin-An Lu2*, Min Xiong1, Jun-Fang Yang1, Jian-Ping Zhang1, Xiao-Su Zhou1, Ting He2#, Pei-Hua Lu1#, Safety and efficacy of autologous or donor-derived CD19 CAR-T Treatment in relapsed B acute lymphocytic leukemia after Allo-HSCT.

    EBMT, March 18-21,2018, oral presentation.

    Junfang Yang1*, Xin-An Lu2*, Xian Zhang1, Min Xiong1, Jian-Ping Zhang1, Xiao-Su Zhou1, Fei-fei Qi2, Ting He2#, Pei-Hua Lu1#, Comparison of CD19 CAR-T cells with distinct co-stimulatory domains in treatment of B-cell acute lymphoblastic leukemia.

    ASCO, June 1-5,2018, presentation in the Poster Session.

    Junfang Yang, Jianqiang Li, Xian Zhang, Fanyong Lv,  Xiaoling Guo, Qinglong Wang,Lin Wang,Dandan Chen,Xiaosu Zhou, Jinhai Ren, Peihua Lu#, A Feasibility and Safety Study of CD19 and CD22 Chimeric Antigen Receptors-modified T Cell Cocktail for Therapy of B Cell Acute Lymphoblastic Leukemia.

    ASH, December 1-4, 2018, oral presentation.

    Xian Zhang, Xin-an Lu, Junfang Yang, Fanyong Lv, Min Xiong, Jianping Zhang, Xiaosu Zhou, Ting He, Peihua Lu#
,Efficacy and Safety of CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy for B-Cell Acute Lymphocytic Leukemia (B-cell ALL) in a Large Cohort Including Patients with Extramedullary Disease(EMD), High Leukemia Burden(HLB), BCR-ABL (+) Mutation,TP53 Mutation, and Post-Transplant Relapse.

    ASH, December 1-4, 2018, oral presentation.

  • 今年2月份我们接待了一例非常罕见的病例,一个...【详细】
    CAR-T(T细胞嵌合抗原受体)作为一种免疫...【详细】
    又一例外院治疗复发的极高危急性B淋巴细胞白血...【详细】
     
    中华人民共和国卫生部
    中华骨髓库
    血液病专科医协体
    湖北省干细胞库